Tracy Ann Vivlemore

Array ( [id] => 16977929 [patent_doc_number] => 20210222166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => LNA BASED NANODEVICE [patent_app_type] => utility [patent_app_number] => 16/625915 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12239 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16025791 [patent_doc_number] => 10675295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Compositions and methods for inhibiting HMGB1 expression [patent_app_type] => utility [patent_app_number] => 16/024355 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 65 [patent_no_of_words] => 24675 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13841195 [patent_doc_number] => 20190024082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => TWO-TAILED SELF-DELIVERING SIRNA [patent_app_type] => utility [patent_app_number] => 16/015440 [patent_app_country] => US [patent_app_date] => 2018-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16015440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13586455 [patent_doc_number] => 20180344776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => Direct Reprogramming of Cells to Cardiac Myocyte Fate [patent_app_type] => utility [patent_app_number] => 15/997422 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16073057 [patent_doc_number] => 20200190515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/618001 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 171125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16618001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590721 [patent_doc_number] => 20180346909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => SYSTEM AND METHOD FOR REVERSIBLE PHOTO-CONTROLLED GENE SILENCING [patent_app_type] => utility [patent_app_number] => 15/992707 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15992707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13958441 [patent_doc_number] => 20190055564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/991326 [patent_app_country] => US [patent_app_date] => 2018-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15991326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13871431 [patent_doc_number] => 20190032056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => STEM-LOOP COMPOSITIONS AND METHODS FOR INHIBITING FACTOR D [patent_app_type] => utility [patent_app_number] => 15/990547 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17466765 [patent_doc_number] => 11273222 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => Antisense nucleic acid targeting PCSK9 [patent_app_type] => utility [patent_app_number] => 16/616724 [patent_app_country] => US [patent_app_date] => 2018-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 17 [patent_no_of_words] => 10180 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956250 [patent_doc_number] => 11060094 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor [patent_app_type] => utility [patent_app_number] => 16/613853 [patent_app_country] => US [patent_app_date] => 2018-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 33153 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17998058 [patent_doc_number] => 11499154 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies [patent_app_type] => utility [patent_app_number] => 16/604121 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 11 [patent_no_of_words] => 14147 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16112271 [patent_doc_number] => 20200208158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => PRODUCTS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/500703 [patent_app_country] => US [patent_app_date] => 2018-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16500703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18029138 [patent_doc_number] => 11512313 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Functionally-interdependent shape switching nucleic acid nanoparticles [patent_app_type] => utility [patent_app_number] => 16/500765 [patent_app_country] => US [patent_app_date] => 2018-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 19 [patent_no_of_words] => 34289 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16500765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206891 [patent_doc_number] => 20200239881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => MORPHOLINO MODIFIED OLIGOMERIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/489836 [patent_app_country] => US [patent_app_date] => 2018-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16489836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16499877 [patent_doc_number] => 10865252 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Lin28-mediated control of let-7 biogenesis [patent_app_type] => utility [patent_app_number] => 15/913323 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 91 [patent_no_of_words] => 37505 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15913323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16499877 [patent_doc_number] => 10865252 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-15 [patent_title] => Lin28-mediated control of let-7 biogenesis [patent_app_type] => utility [patent_app_number] => 15/913323 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 91 [patent_no_of_words] => 37505 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15913323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15268065 [patent_doc_number] => 20190382766 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => FUNCTIONAL LIGANDS TO DRUG COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/488239 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16488239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12909697 [patent_doc_number] => 20180195074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => Compositions and Methods for Inhibiting Expression of RRM2 Genes [patent_app_type] => utility [patent_app_number] => 15/906054 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15906054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12863101 [patent_doc_number] => 20180179541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => Modified L-Nucleic Acid [patent_app_type] => utility [patent_app_number] => 15/897668 [patent_app_country] => US [patent_app_date] => 2018-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267997 [patent_doc_number] => 20190382732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => COMPOSITIONS AND METHODS RELATING TO MYOMIXER-PROMOTED MUSCLE CELL FUSION [patent_app_type] => utility [patent_app_number] => 16/487937 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487937 [rel_patent_id] =>[rel_patent_doc_number] =>)